KRAS Mutation in PDAC: Comparison
View Latest Version
Please note this is a comparison between Version 3 by Lindsay Dong and Version 2 by Meichen Gu.

The vast majority of patients with pancreatic ductal adenocarcinomas harbor KRAS mutations in their tumors. Functionally, mutated KRAS is not only dedicated to tumor cell proliferation, survival and invasiveness, but also causing the immunosuppression in this cancer. 

  • KRAS gene
  • pancreatic ductal adenocarcinoma
  • cancer immunity
  • immune checkpoint blockade
Please wait, diff process is still running!

References

  1. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424. [CrossRef]Vincent, A.; Herman, J.; Schulik, R.; Hruban, R.H.; Goggins, M. Pancreatic cancer. Lancet 2011, 378, 607–620.
  2. Vincent, A.; Herman, J.; Schulik, R.; Hruban, R.H.; Goggins, M. Pancreatic cancer. Lancet 2011, 378, 607–620. [CrossRef]Marabelle, A.; Le, D.T.; Ascierto, P.A.; di Giacomo, A.M.; de Jesus-Acosta, A.; Delord, J.P.; Geva, R.; Gottfried, M.; Penel, N.; Hansen, A.R.; et al. Efficacy of Pembrolizumab in Patients with Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results from the Phase II KEYNOTE-158 Study. J Clin. Oncol. 2020, 38, 1–10.
  3. Sohal, D.P.; Kennedy, E.B.; Cinar, P.; Conroy, T.; Copur, M.S.; Crane, C.H.; Garrido-Laguna, I.; Lau, M.W.; Johnson, T.; Krishnamurthi, S.; et al. Metastatic Pancreatic Cancer: ASCO Guideline Update. J. Clin. Oncol. 2020, 27, 3217–3230. [CrossRef][PubMed]Ribas, A.; Wolchok, J.D. Cancer immunotherapy using checkpoint blockade. Science 2018, 359, 1350–1355.
  4. Marabelle, A.; Le, D.T.; Ascierto, P.A.; di Giacomo, A.M.; de Jesus-Acosta, A.; Delord, J.P.; Geva, R.; Gottfried, M.; Penel, N.; Hansen, A.R.; et al. Efficacy of Pembrolizumab in Patients with Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results from the Phase II KEYNOTE-158 Study. J Clin. Oncol. 2020, 38, 1–10. [CrossRef] [PubMed]Wellenstein, M.D.; de Visser, K.E. Cancer-Cell-Intrinsic Mechanisms Shaping the Tumor Immune Landscape. Immunity 2018, 48, 399–416.
  5. Henriksen, A.; Dyhl-Polk, A.; Chen, I.; Nielsen, D. Checkpoint inhibitors in pancreatic cancer. Cancer Treat. Rev. 2019, 78, 17–30. [CrossRef] [PubMed]Bailey, P.; Chang, D.K.; Nones, K.; Johns, A.L.; Patch, A.M.; Gingras, M.C.; Miller, D.K.; Christ, A.N.; Bruxner, T.J.; Quinn, M.C.; et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 2016, 531, 47–52.
  6. Ribas, A.;Wolchok, J.D. Cancer immunotherapy using checkpoint blockade. Science 2018, 359, 1350–1355. [CrossRef] [PubMed]Gruber, R.; Panayiotou, R.; Nye, E.; Spencer-Dene, B.; Stamp, G.; Behrens, A. YAP1 and TAZ Control Pancreatic Cancer Initiation in Mice by Direct Up-regulation of JAK-STAT3 Signaling. Gastroenterology 2016, 151, 526–539.
  7. Liu, X.; Xu, J.; Zhang, B.; Liu, J.; Liang, C.; Meng, Q.; Hua, J.; Yu, X.; Shi, S. The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: New insights and therapeutic implications. Mol. Cancer. 2019, 18, 184. [CrossRef] [PubMed]Yamamoto, K.; Venida, A.; Yano, J.; Biancur, D.E.; Kakiuchi, M.; Gupta, S.; Sohn, A.S.; Mukhopadhyay, S.; Lin, E.Y.; Parker, S.J.; et al. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. Nature 2020, 581, 100–105.
  8. Wellenstein, M.D.; de Visser, K.E. Cancer-Cell-Intrinsic Mechanisms Shaping the Tumor Immune Landscape. Immunity 2018, 48, 399–416. [CrossRef]Dong, Z.Y.; Zhong, W.Z.; Zhang, X.C.; Su, J.; Xie, Z.; Liu, S.Y.; Tu, H.Y.; Chen, H.J.; Sun, Y.L.; Zhou, Q.; et al. Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma. Clin. Cancer Res. 2017, 23, 3021–3024.
  9. Cox, A.D.; Fesik, S.W.; Kimmelman, A.C.; Luo, J.; Der, C.J. Drugging the undruggable RAS:Mission possible? Nat. Rev. Drug Discov. 2014, 13, 828–851. [CrossRef]Liang, T.; Tong, W.; Ma, S.; Chang, P. Standard therapies: Solutions for improving therapeutic effects of immune checkpoint inhibitors on colorectal cancer. OncoImmunology 2020, 9, 1773205.
  10. [10] Bailey P., Chang D. K. Nones K., Johns A. L., Patch A. M. Gingras M. C., et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016, 531: 47-52.Yun, J.; Rago, C.; Cheong, I.; Pagliarini, R.; Angenendt, P.; Rajagopalan, H.; Schmidt, K.; Willson, J.K.; Markowitz, S.; Zhou, S.; et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 2009, 325, 1555–1559.
  11. [11] Kamisawa T., Wood L. D. Itoi T., Takaori K. Pancreatic cancer. Lancet. 2016, 388:73-85.Vakiani, E.; Janakiraman, M.; Shen, R.; Sinha, R.; Zeng, Z.; Shia, J.; Cercek, A.; Kemeny, N.; D’Angelica, M.; Viale, A.; et al. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J. Clin. Oncol. 2012, 30, 2956–2962.
  12. [12] Gruber R., Panayiotou R., Nye E., Spencer-Dene B., Stamp G., Behrens A. YAP1 and TAZ Control Pancreatic Cancer Initiation in Mice by Direct Up-regulation of JAK-STAT3 Signaling. Gastroenterology. 2016, 151:526-39.Lal, N.; White, B.S.; Goussous, G.; Pickles, O.; Mason, M.J.; Beggs, A.D.; Taniere, P.; Willcox, B.E.; Guinney, J.; Middleton, G.W. KRAS Mutation and Consensus Molecular Subtypes 2 and 3 Are Independently Associated with Reduced Immune Infiltration and Reactivity in Colorectal Cancer. Clin. Cancer Res. 2018, 24, 224–233.
  13. [13] Humpton T. J., Alagesan B., DeNicola G. M., Lu D., Yordanov G. N. Leonhardt C. S., et al. Oncogenic KRAS Induces NIX-Mediated Mitophagy to Promote Pancreatic Cancer. Cancer Discov. 2019, 9:1268-1287.Guinney, J.; Dienstmann, R.; Wang, X.; de Reynies, A.; Schlicker, A.; Soneson, C.; Marisa, L.; Roepman, P.; Nyamundanda, G.; Angelino, P.; et al. The consensus molecular subtypes of colorectal cancer. Nat. Med. 2015, 21, 1350–1356.
  14. [14] Yamamoto K., Venida A., Yano J., Biancur D. E., Kakiuchi M., Gupta S., et al. Autophagy promotes immune evasion of pancre-atic cancer by degrading MHC-I. Nature. 2020, 581:100-105.Ganesh, K.; Stadler, Z.K.; Cercek, A.; Mendelsohn, R.B.; Shia, J.; Segal, N.H.; Diaz, L.A. Immunotherapy in colorectal cancer: Rationale, challenges and potential. Nat. Rev. Gastroenterol. Hepatol. 2019, 16, 361–375.
  15. [15] Blagih J., Zani F., Chakravarty P., Hennequart M., Pilley S., Hobor S., et al. Cancer-Specific Loss of p53 Leads to a Modulation of Myeloid and T Cell Responses. Cell Rep. 2020, 30:481-496.Sivaram, N.; McLaughlin, P.A.; Han, H.V.; Petrenko, O.; Jiang, Y.P.; Ballou, L.M.; Pham, K.; Liu, C.; van der Velden, A.W.; Lin, R.Z. Tumor-intrinsic PIK3CA represses tumor immunogenecity in a model of pancreatic cancer. J. Clin. Investig. 2019, 129, 3264–3276.
  16. [16] Dong Z.Y., Zhong W. Z., Zhang X. C., Su J., Xie Z., Liu S. Y., et al. Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma. Clin Cancer Res. 2017, 23:3021-3024.Yoshimura, A.; Muto, G. TGF-β function in immune suppression. Curr. Top Microbiol. Immunol. 2011, 350, 127–147.
  17. [17] Skoulidis F., Goldberg M. E., Greenawalt D. M., Hellman M. D. Awad M. M. Gainor J. F. et al. STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discov. 2018, 8:822-835.Wang, G.; Wang, J.J.; Yin, P.H.; Xu, K.; Wang, Y.Z.; Shi, F.; Gao, J.; Fu, X.L. Strategies to target energy metabolism in consensus molecular subtype 3 along with Kirsten rat sarcoma viral oncogene homolog mutations for colorectal cancer therapy. J. Cell Physiol. 2019, 234, 5601–5612.
  18. [18] Liang T., Tong W., Ma S., Chang P. Standard therapies: solutions for improving therapeutic effects of immune checkpoint in-hibitors on colorectal cancer. OncoImmunology. 2020, 9:1773205.Zhang, W.; Nandakumar, N.; Shi, Y.; Manzano, M.; Smith, A.; Graham, G.; Gupta, S.; Vietsch, E.E.; Laughlin, S.Z.; Wadhwa, M.; et al. Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma. Sci. Signal. 2014, 7, ra42.
  19. [19] Waters A. M., Der C. J. KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harb Perspect Med. 2018, 8: a0311435.Chang, C.; Qiu, J.; O’Sullivan, D.; Buck, M.D.; Noguchi, T.; Curtis, J.D.; Chen, Q.; Gindin, M.; Gubin, M.M.; van der Windt, G.J.; et al. Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell 2015, 162, 1229–1241.
  20. [20] He P., Yang J. W., Yang V. W., Bialkowska. A. B. Krüppel-like Factor 5, Increased in Pancreatic Ductal Adenocarcinoma, Pro-motes Proliferation, Acinar-to-Ductal Metaplasia, Pancreatic Intraepithelial Neoplasia, and Tumor Growth in Mice. Gastroen-terology. 2018, 154: 1494-1508.Jones, S.A.; Jenkins, B.J. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat. Rev. Immunol. 2018, 18, 773–789.
  21. [21] Zhang W., Nandakumar N., Shi Y., Manzano M., Smith A., Graham G., et al. Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma. Sci Signal. 2014, 7:ra42.Eibl, G.; Rozengurt, E. KRAS, YAP, and obesity in pancreatic cancer: A signaling network with multiple loops. Semin. Cancer Biol. 2019, 54, 50–62.
  22. [22] DeNicola G. M., Karreth F. A., Humpton T. J., Gopinathan A., Wei C., Frese K., Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature. 2011, 475:106-9.Allende, M.T.S.; Zeron-Medina, J.; Hernandez, J.; Macarulla, T.; Balsells, J.; Merino, X.; Allende, H.; Tabernero, J. Overexpression of Yes Associated Protein 1, an Independent Prognostic Marker in Patients with Pancreatic Ductal Adenocarcinoma, Correlated with Liver Metastasis and Poor Prognosis. Pancreas 2017, 46, 913–920.
  23. [23] Chang C., Qiu J., O’Sullivan D., Buck M. D. Noguchi T., Curtis J. D., et al. Metabolic Competition in the Tumor Microenviron-ment Is a Driver of Cancer Progression. Cell. 2015, 162:1229-41.Hingorani, S.R.; Wang, L.; Multani, A.S.; Combs, C.; Deramaudt, T.B.; Hruban, R.H.; Rustgi, A.K.; Chang, S.; Tuveson, D.A. Trp53R172H and KRASG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005, 7, 469–483.
  24. [24] Kottakis F., Nicolay B. N., Roumane A., Karnik R., Gu H., Nagle J. M., et al. LKB loss links serine metabolism to DNA methyla-tion and tumorigenesis. Nature. 2016, 539: 390-395.Fukumura, D.; Kloepper, J.; Amoozgar, Z.; Duda, D.G.; Jain, R.K. Enhancing cancer immunotherapy using antiangiogenics: Opportunities and challenges. Nat. Rev. Clin. Oncol. 2018, 15, 325–340.
  25. [25] Jones S. A., Jenkins B. J. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat Rev Immunol. 2018, 18:773-789.Sodir, N.M.; Kortlever, R.M.; Barthet, V.J.; Campos, T.; Pellegrinet, L.; Kupczak, S.; Anastasiou, P.; Swigart, L.B.; Soucek, L.; Arends, M.J.; et al. MYC Instructs and Maintains Pancreatic Adenocarcinoma Phenotype. Cancer Discov. 2020, 10, 588–607.
  26. [26] Corcoran R. B., Contino G., Deshpande V., Tzatsos A., Conrad C., Benes C. H. et al. STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Res. 2011, 71:5020-9.Johnson, B.A., III; Yarchoan, M.; Lee, V.; Laheru, D.A.; Jaffee, E.M. Strategies for Increasing Pancreatic Tumor Immunogenicity. Clin. Cancer Res. 2017, 23, 1656–1669.
  27. [27] Eibl G., Rozengurt E. KRAS, YAP, and obesity in pancreatic cancer: A signaling network with multiple loops. Semin Cancer Biol. 2019, 54: 50-62.Feig, C.; Jones, J.O.; Kraman, M.; Wells, R.J.B.; Deonarine, A.; Chan, D.S. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergized with anti-PD-L1 immunotherapy in pancreatic cancer. Proc. Natl. Acad. Sci. USA 2013, 110, 20212–20217.
  28. [28] Zhao X., Wang X., Fang L., Lan C., Zheng X., Wang Y., et al. A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer. Cancer Lett. 2017, 402: 61-70.O’Reilly, E.M.; Oh, D.Y.; Dhani, N.; Renouf, D.J.; Lee, M.A.; Sun, W.; Fisher, G.; Hezel, A.; Chang, S.C.; Vlahovic, G.; et al. Durvalumab With or Without Tremelimumab for Patients with Metastatic Pancreatic Ductal Adenocarcinoma: A phase 2 Randomized Clinical Trial. JAMA Oncol. 2019, 5, 1431–1438.
  29. [29] Allende M., Zeron-Medina J., Hernandez J., Macarulla T., Balsells J., Merino X., et al. Overexpression of Yes Associated Protein 1, an Independent Prognostic Marker in Patients With Pancreatic Ductal Adenocarcinoma, Correlated With Liver Metastasis and Poor Prognosis. Pancreas. 2017, 46:913-920.Xie, C.; Duffy, A.G.; Brar, G.; Fioravanti, S.; Mabry-Hrones, D.; Walker, M.; Bonilla, C.M.; Wood, B.J.; Citrin, D.E.; Ramirez, E.M.G.; et al. Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Clin. Cancer Res. 2020, 26, 2318–2326.
  30. [30] Yang W., Yang S., Zhang F., Cheng F., Wang X., Rao J. Influence of the Hippo-YAP signaling pathway on tumor associated macrophages (TAMs) and its implications on cancer immunosuppressive microenvironment. Ann Transl Med. 2020, 8:399.Weiss, G.J.; Waypa, J.; Blaydorn, L.; Coats, J.; McGahey, K.; Sangal, A.; Niu, J.; Lynch, C.A.; Farley, J.H.; Khemka, V. A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PmebroPlus). Br. J. Cancer 2017, 117, 33–40.
  31. [31] Hingorani S. R., Wang L., Multani A. S., Combs C., Deramaudt T. B. Hruban R. H., et al. Trp53R172H and KRASG12D cooper-ate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell. 2005, 7:469-83.Aglietta, M.; Barone, C.; Sawyer, M.B.; Moore, M.J.; Miller, W.H., Jr.; Bagalà, C.; Colombi, F.; Cagnazzo, C.; Gioeni, L.; Wang, E.; et al. A phase I dose, escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer. Ann. Oncol. 2014, 25, 1750–1755.
  32. [32] Murakami S., Shabhazian D., Surana R., Zhang W., Chen H., Graham G. T., Yes-associated protein mediates immune repro-gramming in pancreatic ductal adenocarcinoma. Oncogene. 2017, 36:1232-1244.Fukuoka, S.; Hara, H.; Takahashi, N.; Kojima, T.; Kawazoe, A.; Asayama, M.; Yoshii, T.; Kotani, D.; Tamura, H.; Mikamoto, Y.; et al. Regorafenib Plus Nivolumab in Patients with Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603). J. Clin. Oncol. 2020, 38, 2053–2061.
  33. [33] Gan L. L., Hii L.W., Wong S. F., Leong C. O., Mai C. W. Molecular Mechanisms and Potential Therapeutic Reversal of Pancreatic Cancer-Induced Immune Evasion. Cancers (Basel). 2020, 12:1872.
  34. [34] Sivaram N., McLaughlin P. A., Han H. V., Petrenko O., Jiang Y. P., Ballou L. M., et al. Tumor-intrinsic PIK3CA represses tumor immunogenecity in a model of pancreatic cancer. J Clin Invest. 2019, 129:3264-3276.
  35. [35] Fukumura D., Kloepper J., Amoozgar Z., Duda D. G., Jain R. K. Enhancing cancer immunotherapy using antiangiogenics: op-portunities and challenges. Nat Rev Clin Oncol. 2018, 15:325-340.
  36. [36] Li S., Xu H. X., Wu C. T., Wang W. Q., Jin W., Gao H. L., et al. Angiogenesis in pancreatic cancer: current research status and clinical implications. Angiogenesis. 2019, 22:15-36.
  37. [37] Sodir N.M., Kortlever R. M., Barthet V. J. A., Campos T., Pellegrinet L., Kupczak S., et al. MYC Instructs and Maintains Pancre-atic Adenocarcinoma Phenotype. Cancer Discov. 2020, 10:588-607.
  38. [38] Lu C., Paschall A. V., Shi H., Savage N., Waller J.L., Sabbatini M. E., et al. The MLL1-H3K4me3 Axis-Mediated PD-L1 Expres-sion and Pancreatic Cancer Immune Evasion. J. Natl. Cancer Inst. 2017, 109: djw283.
  39. [39] Johnson B. A. 3rd., Yarchoan M., Lee V., Laheru D. A., Jaffee E. M. Strategies for Increasing Pancreatic Tumor Immunogenicity. Clin Cancer Res. 2017, 23:1656-1669.
  40. [40] Joyce J. A., Fearon D. T. T cell exclusion, immune privilege, and the tumor microenvironment. Science. 2015, 348: 74-80.
  41. [41] Feig C., Jones J. O., Kraman M., Wells R. J. B., Deonarine A., Chan D. S., Targeting CXCL12 from FAP-expressing carcino-ma-associated fibroblasts synergized with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A. 2013, 110: 20212-7.
  42. [42] Beatty G. L., Winograd R., Evans R. A., Long K. B., Luque S. L., Lee J. W., et al. Exclusion of T cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6C(low) F4/80(+) Extracuumoral Macrophages. Gastroenterology. 2015, 149:201-10.
  43. [43] O’Reilly E.M., Oh D.Y., Dhani N., Renouf D.J. Lee M. A., Sun W., et al. Durvalumab With or Without Tremelimumab for Pa-tients With Metastatic Pancreatic Ductal Adenocarcinoma: A phase 2 Randomized Clinical Trial. JAMA Oncol. 2019, 5: 1431-8.
  44. [44] Luke J.J., Lemons J.M., Karrison T. G., Pitroda S.P., Melotek J. M., Zha Y. Y., et al. Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol. 2018, 36:1611-1618.
  45. [45] Xie C., Duffy A. G., Brar G., Fioravanti S., Mabry-Hrones D., Walker M., et al. Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2020, 26:2318-2326.
  46. [46] Wang Q., Ju X., Wang J., Fan Y., Ren M., Zhang H. Immunogenic cell death in anticancer chemotherapy and its impact on clini-cal studies. Cancer Lett. 2018, 438: 17-23.
  47. [47] Weiss G. J., Waypa J., Blaydorn L., Coats J., McGahey K., Sangal A., et al. A phase Ib study of pembrolizumab plus chemother-apy in patients with advanced cancer (PmebroPlus). Br J Cancer. 2017, 117:33-40.
  48. [48] Kamath S. D., Kalyan A., Kircher S., Nimeiri H., Fought A.J., Benson 3rd Al., et al. Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A phase Ib Study. Oncologist. 2020, 25: e808-e815.
  49. [49] Dawood S., Austin L., Cristofanilli M. Cancer stem cells: implications for cancer therapy. Oncology (Williston Park). 2014, 28:1101-7.
  50. [50] Riaz N., Havel J. J., Makarov V., Desrichard A., Urba W. J., Sims J. S., et al. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell. 2017, 171: 934-949.
  51. [51] Conroy T., Desseigne F., Ychou M., Bouché O., Guimbaud R., Bécouarn Y., et al. FOLFIRINOX versus gemcitabine for meta-static pancreatic cancer. N Engl J Med. 2011, 364:1817-25.
  52. [52] Von Hoff D. D., Ervin T., Arena F. P., Chiorean E. G., Infante J., Moore M., et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013, 369:1691-703.
  53. [53] Schumacher T.N., Scheper W., Kvistborg P. Cancer Neoantigens. Annu Rev Immunol. 2019, 37:173-200.
  54. [54] Aglietta M., Barone C., Sawyer M. B., Moore M. J., Miller Jr W. H., Bagalà C., et al. A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer. Ann Oncol. 2014, 25:1750-5.
  55. [55] Wainberg Z. A., Hochster H.S., Kim E., George B., Kalyan A., Chiorean E.G., et al. Phase I study of nivolumab (nivo) + nab-paclitaxel (nab-P) + gemcitabine (Gem) in advanced pancreatic cancer (APC). J Clin Oncol. 2019, 37:298.
  56. [56] Wainberg Z. A., Hochster H. S., George B., Gutierrez M., Johns M. E., Chiorean E. G., et al. Phase I study of nivolumab (nivo) + nab-paclitaxel (nab-P) ± gemcitabine (Gem) in solid tumors: interim results from the pancreatic cancer (PC) cohorts [abstracts]. J Clin Oncol. 2017, 35: 412.
  57. [57] Renouf D.J., Dhani N.C., Kavan P., Jonker D.J., Wei AC-C., Hsu T., et al. The Canadian Cancer Trials Group PA.7 trial: results from the safety run in of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) versus GEM, nab-P, durvalumab (D), and tremelimumab (T) as first-line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC). J Clin Oncol. 2018, 36: 349.
  58. [58] Borazanci E.H., Jameson G.S., Borad M.J., Ramanathan R.K., Korn R.L., Caldwell L., et al. A phase II pilot trial of nivolumab (N) + albumin bound paclitaxel (AP) + paricalcitol (P) + cisplatin (C) + gemcitabine (G) (NAPPCG) in patients with previously un-treated metastatic pancreatic ductal adenocarcinoma (PDAC). J Clin Oncol. 2018, 36:358.
  59. [59] Luchini C., Brosens L. A. A., Wood L. D. Chatterjee D., Shin J. II., Sciammarella C., et al. Comprehensive characterization of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications. Gut. 2020. Online ahead of print.
  60. [60] Allen E., Jabouille A., Rivera Lee B., Lodewijckx I., Missiaen R., Steri V., et al. Combined antiangiogenic and anti-PD-L1 therapy stimulates immunity through HEV formation. Sci Transl Med. 2017, 9: eaak9679.
  61. [61] Mace T. A., Shakya R., Pitaarresi J. R., Swanson B., McQuinn C. W., Loftus S., et al. IL-6 and PD-L1 antibody blockade combina-tion therapy reduces tumour progression in murine models of pancreatic cancer. Gut. 2018, 67:320-332.
  62. [62] Zhang Q., Green M. D., Lang X., Lazarus J., Parsels J. D., Wei S., Inhibition of ATM Increases Interferon Signaling and Sensitizes Pancreatic Cancer to Immune Checkpoint Blockade Therapy. Cancer Res. 2019, 79:3940-3951.
  63. [63] Zhu Y., Knolhoff B.L., Meyer M.A., Nywening T.M., West B.L., Luo J., et al. CSF1/CSF1R blockade reprograms tu-mor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 2014, 74:5057-69.
  64. [64] Stewart R. A., Pilié P.G., Yap T. A. Development of PARP and Immune-Checkpoint Inhibitor Combinations. Cancer Res. 2018, 78: 6717-6725.
  65. [65] Keenan B. P., Saenger Y., Kafrouni M. I., Leubner A., Lauer P., Maitra A., et al. A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice. Gastroenterology. 2014, 146: 1784-94.
  66. [66] Jiang H., Hegde S., Knolhoff B. L., Zhu Y., Herndon J. M., Meyer M. A., et al. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nat Med. 2016, 22:851-60.
  67. [67] Sanford D. E., Belt B. A., Panni R. Z., Mayer A., Deshpande A. D., Carpenter D., et al. Inflammatory monocyte mobilization de-creases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis. Clin Cancer Res. 2013, 19:3404-15.
  68. [68] Blair A.B., Kleponis J., Thomas D.L. 2nd., Muth S. T., Murphy A. G., Kim V., et al. IDO1 inhibition potentiates vaccine-induced immunity against pancreatic adenocarcinoma. J Clin Invest. 2019, 129:1742-1755.
  69. [69] Burrack A. L., Spartz E. J., Raynor J. F., Wang I., Olson M., Stromnes I.M. Combination PD-1 and PD-L1 Blockade Promotes Durable Neoantigen-Specific T Cell-Mediated Immunity in Pancreatic Ductal Adenocarcinoma. Cell Rep. 2019, 28:2140-2155.
  70. [70] Christenson E. S., Jaffee E., Azad N. S. Current and emerging therapies for patients with advanced pancreatic ductal adenocar-cinoma: a bright future. Lancet Oncol. 2020, 21: e135-e145.
  71. [71] Nollmann FI., Ruess DA. Targeting Mutant KRAS in Pancreatic Cancer: Futile or Promising? Biomedicines. 2020,8(8):281.
  72. [72] Canon J., Rex K., Saiki A.Y., Mohr C., Cooke K., Bagal D., et al. The clinical KRAS(G12C) inhibitor AMG510 drives anti-tumour immunity. Nature. 2019, 575(7781):217-223.
  73. [73] Hallin J., Engstrom L.D., Hargis L., Calinisan A., Aranda R., Briere D. M., et al. The KRASG12C Inhibitor MRTX849 Provides In-sight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients. Cancer Discov. 2020, 10(1): 54-71.
  74. [74] Hong D. S., Fakih M. G., Strickler J. H., Desai J., Durm G. A., Shapiro G.I., et al. KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. N Engl J Med. 2020, 383(13):1207-1217.
  75. [75] Briere D., Calinisan A., Aranda R., Sudhakar N., Hargis L., Gatto S., The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Leads to Durable Complete Responses in Combination with Anti-PD-1 Therapy in a Syngeneic Mouse Model. AACR 2019. [Abstract]
  76. [76] Tran E., Robbins P.F., Lu Y.C., Prickett T.D., Gartner J.J., Jia L., et al. T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. N Engl J Med. 2016, 375(23):2255-2262.
  77. [77] Vakiani E., Janakiraman M., Shen R., Sinha R., Zeng Z., Shia J., et al. Comparative genomic analysis of primary versus meta-static colorectal carcinomas. J Clin Oncol. 2012, 30: 2956-2962.
  78. [78] Yoshimura A., Muto G. TGF-β function in immune suppression. Curr Top Microbiol Immunol. 2011, 350:127-47.
  79. [79] Boutin A. T., Liao W. T., Wang M., Hwang S. S., Karpinets T. V., Cheung H., et al. Oncogenic KRAS drives invasion and main-tains metastases in colorectal cancer. Genes Dev. 2017, 31:370-382.
  80. [80] Smeby J., Sveen A., Merok M. A., Danielssen S. A., Eilertsen I. A., Guren M. G., et al. CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer. Ann Oncol. 2018, 29:1227-1234.
  81. [81] Guinney J., Dienstmannn R., Wang X., deReyniès A., Schlicker A., Soneson C., et al. The consensus molecular subtypes of colo-rectal cancer. Nat Med. 2015, 21:1350-6.
  82. [82] Le D. T., Kim T. W., Van Cutsem E., Geva R., Jäger D., Hara H., et al. Phase II Open-Label Study of Pembrolizumab in Treat-ment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164. J Clin Oncol. 2020, 38:11-19.
  83. [83] Overman M. J., Lonardi S., Wong K. Y. M., Lenz H. J., Gelsomino F., Aglietta M., et al. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. J Clin Oncol. 2018, 36:773-779.
  84. [84] Andre T., Shiu K. K., Kim T. W., Jensen B. V., Jensen L. H., Punt C., et al. KEYNOTE-177: Phase 3, Open-label, randomized study of first-line pembrolizumab (Pembro) versus investigator-choice chemotherapy for mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal carcinoma (mCRC)[Abstract]. J Clin Oncol. 2018, 4-suppl (Feb-ruary 26th).
  85. [85] Ganesh K., Stadler Z. K., Cercek A., Mendelsohn R. B., Shia J., Segal N. H., et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019, 16:361-375.
  86. [86] Lal N., White B. S., Goussous G., Pickles O., Mason M. J., Beggs A. D., et al. KRAS Mutation and Consensus Molecular Subtypes 2 and 3 Are Independently Associated with Reduced Immune Infiltration and Reactivity in Colorectal Cancer. Clin Cancer Res. 2018, 24:224-233.
  87. [87] Liao W., Overman M. J., Boutin A. T., Shang X., Zhao D., Dey P., et al. KRAS-IRF2 Axis Drives Immune Suppression and Im-mune Therapy Resistance in Colorectal Cancer. Cancer Cell. 2019, 35:559-572.
  88. [88] Tran E., Ahmadzadeh M., Lu Y. C., Gros A., Turcotte S., Robbins P. F., et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science. 2015, 350:1387-90.
  89. [89] Yuki S., et al. Short-term results of VOLTAGE-A: Nivolumab monotherapy and subsequent radical surgery following preoper-ative chemoradiotherapy in patients with microsatellite stable and microsatellite instability-high locally advanced rectal can-cer. 2020 ASCO annual meeting. [Abstract 4100]
  90. [90] Ghiringhelli F., et al. Durvalumab and tremelimumab in combination with FOLFOX in patients with RAS-mutated, microsatel-lite-stable, previously untreated metastatic colorectal cancer (mCRC): Results of the first intermediate analysis of the phase Ib/II MEDETREME trial. J Clin Oncol. 2020 38: 15-suppl, 3006.
  91. [91] Shota F., et al. Regorafenib plus nivolumab in patients with advanced gastric (GC) or colorectal cancer (CRC): An open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603). 2019 ASCO annual meeting. [Abstract]
  92. [92] Wang G., Wang J. J., Yin P. H., Xu K., Wang Y. Z., Shi F., et al. Strategies to target energy metabolism in consensus molecular subtype 3 along with Kirsten rat sarcoma viral oncogene homolog mutations for colorectal cancer therapy. J Cell Physiol. 2019, 234:5601-5612.
  93. [93] Yun J., Rago C., Cheong I., Pagliarini R., Angenendt P., Rajagopalan H., et al. Glucose deprivation contributes to the develop-ment of KRAS pathway mutations in tumor cells. Science. 2009, 325: 1555-9.
  94. [94] Kerr E. M., Gaude E., Turrell F. K., Frezza C., Martins C. P. Mutant KRAS copy number defines metabolic reprogramming and therapeutic susceptibilities. Nature. 2016, 531: 110-3.
  95. [95] Gu M., Xu T., Chang P. KRAS/LKB1 and KRAS/TP53 co-mutations create divergent immune signatures in lung adenocarcino-mas. Ther Adv Med Oncol. 2020, ahead of print.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
Feedback